Capricor Therapeutics
CAPR
120 hedge funds and large institutions have $174M invested in Capricor Therapeutics in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 46 increasing their positions, 25 reducing their positions, and 20 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 25
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
47% more call options, than puts
Call options by funds: $17M | Put options by funds: $11.6M
11% more funds holding
Funds holding: 108 → 120 (+12)
2% more ownership
Funds ownership: 38.11% → 40.11% (+2%)
27% less capital invested
Capital invested by funds: $239M → $174M (-$65.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
+$4.92M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.76M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.32M |
| 4 |
SCM
Superstring Capital Management
New York
|
+$2.58M |
| 5 |
Morgan Stanley
New York
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$9.85M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.07M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.07M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.56M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.45M |
CAPR Hedge Fund Activity: Q1 2025 in Review
120 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2025, worth a combined $174M — down 27% from $239M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CAPR positions and 20 closed out — a net gain of 12 holders — while 46 added to existing stakes and 25 trimmed.
The largest buyer was Pier Capital, opening a new position worth an estimated $4.92M. The largest seller was Altium Capital Management, exiting entirely with an estimated $9.85M sold.
- 120 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2025, up from 108 in Q4 2024.
- Funds reported $174M of Capricor Therapeutics stock for Q1 2025, down 27% quarter-over-quarter.
- 32 funds opened new Capricor Therapeutics positions in Q1 2025 and 20 closed out, a net change of +12 holders.
- The largest Capricor Therapeutics buyer in Q1 2025 was Pier Capital, an estimated $4.92M added.
- The largest Capricor Therapeutics seller in Q1 2025 was Altium Capital Management, an estimated $9.85M sold.
Based on aggregated 13F filings for Q1 2025.